{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:25:38Z","timestamp":1789626338065,"version":"build-2803163510"},"reference-count":43,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deputyship for Research &amp; Innovation, \u201cMinistry of Education\u201d in Saudi Arabia","award":["IFKSUDR_H193"],"award-info":[{"award-number":["IFKSUDR_H193"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Introduction: Ondansetron is a drug that is routinely prescribed for the management of nausea and vomiting associated with cancer, radiation therapy, and surgical operations. It is mainly metabolized in the liver, and it might accumulate in patients with hepatic impairment and lead to unwanted adverse events. Methods: A physiologically based pharmacokinetic (PBPK) model was developed to predict the exposure of ondansetron in healthy and liver cirrhosis populations. The population-based PBPK simulator PK-Sim was utilized for simulating ondansetron exposure in healthy and liver cirrhosis populations. Results: The developed model successfully described the pharmacokinetics of ondansetron in healthy and liver cirrhosis populations. The predicted area under the curve, maximum systemic concentration, and clearance were within the allowed twofold range. The exposure of ondansetron in the population of Child\u2013Pugh class C has doubled in comparison to Child\u2013Pugh class A. The dose has to be adjusted for liver cirrhosis patients to ensure comparable exposure to a healthy population. Conclusion: In this study, the developed PBPK model has described the pharmacokinetics of ondansetron successfully. The PBPK model has been successfully evaluated to be used as a tool for dose adjustments in liver cirrhosis patients.<\/jats:p>","DOI":"10.3390\/ph16121693","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T06:01:07Z","timestamp":1701842467000},"page":"1693","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3924-593X","authenticated-orcid":false,"given":"Faleh","family":"Alqahtani","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah H.","family":"Alruwaili","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Alasmari","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan A.","family":"Almazroa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled S.","family":"Alsuhaibani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-8583","authenticated-orcid":false,"given":"Muhammad F.","family":"Rasool","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkarim F.","family":"Alruwaili","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Unit, Department of Pharmaceutical Services, Dallah Hospital, Riyadh 12381, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5323-5781","authenticated-orcid":false,"given":"Sary","family":"Alsanea","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"ref_1","unstructured":"European Medicines Agency (2023, May 15). Updated Signal Assessment Report on Birth Defects Following In-Utero Exposure during the First Trimester of Pregnancy Arising from Recent Publications with Ondansetron 1. 2019, Volume 31. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/updated-signal-assessment-report-birth-defects-following-utero-exposure-during-first-trimester_en.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-016-0663-3","article-title":"Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting","volume":"76","author":"Kovac","year":"2016","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FPC.0000000000000369","article-title":"PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics","volume":"29","author":"Huddart","year":"2019","journal-title":"Pharmacogenet. Genom."},{"key":"ref_4","first-page":"1","article-title":"Randomized Controlled Trial of Ondansetron vs. Prochlorperazine in Adults in the Emergency Department","volume":"12","author":"Patka","year":"2011","journal-title":"West. J. Emerg. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/AOG.0000000000001388","article-title":"Ondansetron Use in Pregnancy and Birth Defects","volume":"127","author":"Carstairs","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.7-5-424","article-title":"5-HT3-Receptor Antagonists for the Treatment of Nausea and Vomiting: A Reappraisal of Their Side-Effect Profile","volume":"7","author":"Goodin","year":"2002","journal-title":"Oncologist"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/ALN.0b013e31817fd8c8","article-title":"Droperidol and Ondansetron-Induced QT Interval Prolongation: A Clinical Drug Interaction Study","volume":"109","author":"Charbit","year":"2008","journal-title":"Anesthesiology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00003088-199529020-00004","article-title":"Ondansetron Clinical Pharmacokinetics","volume":"29","author":"Roila","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.2042-7158.1996.tb03973.x","article-title":"Clinical Pharmacokinetics of Ondansetron. A Review","volume":"48","author":"Simpson","year":"1996","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cpt.5","article-title":"Ondansetron Pharmacokinetics in Pregnant Women and Neonates: Towards a New Treatment for Neonatal Abstinence Syndrome","volume":"97","author":"Elkomy","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","article-title":"Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: A Transition from Academic Curiosity to Regulatory Acceptance","volume":"2","author":"Jamei","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/psp4.12134","article-title":"Applied Concepts in PBPK Modeling: How to Build a PBPK\/PD Model","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/bcp.14456","article-title":"Physiologically Based Pharmacokinetic-Pharmacodynamic Evaluation of Meropenem plus Fosfomycin in Paediatrics","volume":"87","author":"Martins","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1111\/bcp.15731","article-title":"Physiologically Based Pharmacokinetic Modelling to Inform Combination Dosing Regimens of Ceftaroline and Daptomycin in Special Populations","volume":"89","author":"Martins","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101675","DOI":"10.1016\/j.jsps.2023.06.008","article-title":"A Physiologically Based Pharmacokinetic Model of Cefepime to Predict Its Pharmacokinetics in Healthy, Pediatric and Disease Populations","volume":"31","author":"Zamir","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rasool, M.F., Khalid, S., Majeed, A., Saeed, H., Imran, I., Mohany, M., Al-Rejaie, S.S., and Alqahtani, F. (2019). Development and Evaluation of Physiologically Based Pharmacokinetic Drug\u2013Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11110578"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40262-015-0253-7","article-title":"A Physiologically Based Pharmacokinetic Drug\u2013Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows","volume":"54","author":"Rasool","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","article-title":"Physiology-Based Simulations of a Pathological Condition","volume":"47","author":"Edginton","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jps.2600800913","article-title":"Determination of Ondansetron in Plasma and Its Pharmacokinetics in the Young and Elderly","volume":"80","author":"Colthup","year":"1991","journal-title":"J. Pharm. Sci."},{"key":"ref_21","first-page":"156","article-title":"Comparison of the Pharmacokinetics of an Ondansetron Solution (8 mg) When Administered Intravenously, Orally, to the Colon, and to the Rectum","volume":"11","author":"Hsyu","year":"1994","journal-title":"Pharm. Res. Off. J. Am. Assoc. Pharm. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2125.1993.tb04164.x","article-title":"The Pharmacokinetics of Intravenous Ondansetron in Patients with Hepatic Impairment","volume":"35","author":"Blake","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2125.1994.tb04294.x","article-title":"The Pharmacokinetics of Ondansetron after Intravenous Injection in Healthy Volunteers Phenotyped as Poor or Extensive Metabolisers of Debrisoquine","volume":"37","author":"Ashforth","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/clpt.1992.7","article-title":"Age and Gender Effects on Ondansetron Pharmacokinetics: Evaluation of Healthy Aged Volunteers","volume":"51","author":"Pritchard","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/jps.2600830717","article-title":"Ondansetron Absorption in Adults: Effect of Dosage Form, Food, and Antacids","volume":"83","author":"Bozigian","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"ref_26","first-page":"59","article-title":"Bioequivalence Study of 2 Orodispersible Formulations of Ondansetron 8 Mg in Healthy Volunteers","volume":"62","author":"Rios","year":"2012","journal-title":"Arzneim.-Forsch.\/Drug Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/ajhp\/57.11.1046","article-title":"Pharmacokinetics of Three Formulations of Ondansetron Hydrochloride in Healthy Volunteers: 24-Mg Oral Tablet, Rectal Suppository, and i.v. Infusion","volume":"57","author":"Vandenberg","year":"2000","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/j.1552-4604.1994.tb02038.x","article-title":"Oral Ondansetron Pharmacokinetics: The Effect of Chemotherapy","volume":"34","author":"Hsyu","year":"1994","journal-title":"J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/j.1552-4604.1996.tb04190.x","article-title":"Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency","volume":"36","author":"Figg","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.2042-7158.2012.01534.x","article-title":"Integration of Dissolution into Physiologically-Based Pharmacokinetic Models III: PK-Sim \u00c2","volume":"64","author":"Willmann","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/00498250701485575","article-title":"The Metabolism of the 5HT3 Antagonists Ondansetron, Alosetron and GR87442 I: A Comparison of In Vitro and In Vivo Metabolism and In Vitro Enzyme Kinetics in Rat, Dog and Human Hepatocytes, Microsomes and Recombinant Human Enzymes","volume":"37","author":"Somers","year":"2007","journal-title":"Xenobiotica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s10856-012-4702-7","article-title":"Solid Lipid Nanoparticles of Ondansetron HCl for Intranasal Delivery: Development, Optimization and Evaluation","volume":"23","author":"Joshi","year":"2012","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1124\/dmd.108.020479","article-title":"Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds","volume":"36","author":"Obach","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/15287394.2019.1652215","article-title":"Model Qualification of the PK-Sim\u00ae Pediatric Module for Pediatric Exposure Assessment of CYP450 Metabolized Compounds","volume":"82","author":"Yun","year":"2019","journal-title":"J. Toxicol. Environ. Health-Part A Curr. Issues"},{"key":"ref_35","first-page":"S21","article-title":"The Clinical Pharmacology of Ondansetron","volume":"25","author":"Blackwell","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK Models for the Prediction of In Vivo Performance of Oral Dosage Forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/cpt.905","article-title":"Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children","volume":"104","author":"Zhou","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0009-9236(99)70130-X","article-title":"The Effect of Rifampin on the Pharmaco-Kinetics of Oral and Intravenous Ondansetron","volume":"65","author":"Villikka","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/psp4.39","article-title":"A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates under Liver Cirrhosis Conditions","volume":"4","author":"Li","year":"2015","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An Add-in Program for Pharmacokinetic and Pharmacodynamic Data Analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1208\/s12248-018-0277-7","article-title":"PBPK and Its Virtual Populations: The Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol","volume":"21","author":"Vermeulen","year":"2019","journal-title":"AAPS J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/dmd.120.090969","article-title":"Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach","volume":"48","author":"Rasool","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1124\/dmd.118.085605","article-title":"Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy","volume":"47","author":"Pierrillas","year":"2019","journal-title":"Drug Metab. Dispos."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/12\/1693\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:34:00Z","timestamp":1760132040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/12\/1693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ph16121693"],"URL":"https:\/\/doi.org\/10.3390\/ph16121693","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}